Immuneering is a clinical-stage oncology company seeking to develop potential medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Company profile
Ticker
IMRX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Immuneering Securities Corporation • BioArkive, Inc. ...
IMRX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Results of Operations and Financial Condition
1 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
2 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Results of Operations and Financial Condition
3 Aug 23
Transcripts
Latest ownership filings
SC 13G/A
Cormorant Asset Management, LP
15 Apr 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Apr 24
SC 13G/A
BlackRock Inc.
5 Apr 24
4
Bihua Chen
3 Apr 24
SC 13G/A
Merrin Investors LLC
27 Mar 24
4
Thomas J. Schall
25 Mar 24
4
Peter Feinberg
25 Mar 24
4
Harold Eugene Brakewood
25 Mar 24
4
Mallory Morales
25 Mar 24
4
Leah R Neufeld
21 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.04 mm | 68.04 mm | 68.04 mm | 68.04 mm | 68.04 mm | 68.04 mm |
Cash burn (monthly) | 11.99 mm | 698.13 k | 4.64 mm | 4.67 mm | 4.01 mm | 4.08 mm |
Cash used (since last report) | 83.16 mm | 4.84 mm | 32.19 mm | 32.42 mm | 27.80 mm | 28.28 mm |
Cash remaining | -15.12 mm | 63.20 mm | 35.85 mm | 35.62 mm | 40.24 mm | 39.76 mm |
Runway (months of cash) | -1.3 | 90.5 | 7.7 | 7.6 | 10.0 | 9.7 |
Institutional ownership, Q3 2023
65.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 54 |
Opened positions | 8 |
Closed positions | 4 |
Increased positions | 24 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 101.75 bn |
Total shares | 19.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cormorant Asset Management | 4.20 mm | $32.29 bn |
T. Rowe Price | 3.53 mm | $27.14 mm |
BLK Blackrock | 2.51 mm | $19.29 bn |
Merrin Investors | 2.41 mm | $0.00 |
Citadel Advisors | 2.07 mm | $15.87 bn |
Vanguard | 1.04 mm | $8.02 bn |
FMR | 612.17 k | $4.70 bn |
GS Goldman Sachs | 482.93 k | $3.71 bn |
Geode Capital Management | 432.70 k | $3.32 bn |
STT State Street | 361.30 k | $2.77 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 2.9 | 398,600 | 1.16 mm | 2,895,273 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 2.97 | 280 | 831.60 | 3,293,873 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 2.98 | 10 | 29.80 | 3,294,153 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 3.01 | 10 | 30.10 | 3,294,163 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 3.03 | 600 | 1.82 k | 3,294,173 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 3.05 | 100 | 305.00 | 3,294,773 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 3.065 | 300 | 919.50 | 3,294,873 |
1 Apr 24 | Cormorant Asset Management | Class A Common Stock | Sell | Dispose S | Yes | No | 3.07 | 100 | 307.00 | 3,295,173 |
22 Mar 24 | Harold Eugene Brakewood | Class A Common Stock | Buy | Acquire P | No | No | 2.568 | 3,900 | 10.02 k | 3,900 |
22 Mar 24 | Peter Feinberg | Class A Common Stock | Buy | Acquire P | No | No | 2.5485 | 25,000 | 63.71 k | 111,766 |
News
Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
12 Apr 24
Immuneering Presented Preclinical Data At AACR annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
9 Apr 24
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
27 Mar 24
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
18 Mar 24
Press releases
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
9 Apr 24
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
3 Apr 24
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27 Mar 24
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
19 Mar 24
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
14 Mar 24